This study will compare two regional anesthesia strategies for pain management after total knee arthroplasty in adults. Both strategies use an adductor canal block (ACB) to provide analgesia while preserving quadriceps muscle strength. The ACB is then combined with either a sacral erector spinae plane block (S-ESPB) or an iPACK (infiltration between the popliteal artery and the posterior capsule of the knee) block to improve posterior knee analgesia. All patients will receive an ultrasound-guided adductor canal block with 20 mL of 0.2% ropivacaine. They will then be randomly assigned to one of two groups: Group 1: ACB combined with a sacral erector spinae plane block (S-ESPB) using 20 mL of 0.2% ropivacaine. Group 2: ACB combined with an iPACK block using 20 mL of 0.2% ropivacaine. Both techniques aim to provide effective postoperative analgesia while minimizing motor blockade and allowing for early mobilization. It is not known whether combining ACB with S-ESPB or with iPACK provides superior pain control, reduces opioid requirements, or results in better functional recovery after total knee arthroplasty. The main purpose of this study is to compare the time to first rescue analgesia and overall postoperative pain control between the two regional anesthesia strategies. The study will also evaluate opioid consumption, motor function, functional mobility, side effects, and block-related complications. We hypothesize that both combinations will provide effective analgesia, but their impact on pain intensity, duration of analgesia, and functional recovery may differ.
Total knee arthroplasty (TKA) is associated with significant postoperative pain, which can limit early mobilization, delay rehabilitation, and increase opioid use. Inadequate pain control may lead to complications such as decreased range of motion, prolonged hospitalization, and reduced patient satisfaction. Regional anesthesia techniques are a cornerstone of multimodal analgesia protocols for TKA. The adductor canal block (ACB) is a motor-sparing technique that targets the saphenous nerve and nerve to vastus medialis while largely preserving quadriceps strength. However, ACB alone may not provide sufficient analgesia for posterior knee structures. To address this limitation, it is often combined with other blocks that target posterior knee innervation. The iPACK (infiltration between the popliteal artery and the posterior capsule of the knee) block is designed to anesthetize the articular branches supplying the posterior capsule of the knee without causing significant motor block. The sacral erector spinae plane block (S-ESPB) is a more proximal truncal block, which may provide analgesia to the posterior knee and surrounding structures through spread of local anesthetic in the fascial planes. This randomized controlled trial will compare two regional anesthesia strategies in patients undergoing total knee arthroplasty: Adductor canal block (ACB) combined with sacral erector spinae plane block (S-ESPB). Adductor canal block (ACB) combined with iPACK block. In both groups, 20 mL of 0.2% ropivacaine will be used for each block (ACB + S-ESPB or ACB + iPACK). All patients will receive standard perioperative care and multimodal analgesia according to institutional protocols. The primary outcome of the study is the time to first rescue analgesia within 48 hours after surgery. Secondary outcomes include pain intensity at rest and during movement, total opioid consumption, motor function (quadriceps strength), postoperative nausea and vomiting, hemodynamic events, block-related complications, time to first mobilization, and patient satisfaction with pain management. The study aims to determine whether combining ACB with S-ESPB or with iPACK results in better analgesia and functional outcomes after TKA. The results may help optimize regional anesthesia protocols for total knee arthroplasty and improve postoperative recovery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
80
Ultrasound-guided adductor canal block performed with 20 mL of 0.2% ropivacaine injected around the saphenous nerve within the adductor canal. Used in both study arms as part of the regional anesthesia protocol for total knee arthroplasty.
Ultrasound-guided sacral erector spinae plane block performed with 20 mL of 0.2% ropivacaine injected deep to the erector spinae muscle at the sacral level. Used in combination with ACB in the ACB + S-ESPB group.
Ultrasound-guided iPACK block performed with 20 mL of 0.2% ropivacaine injected between the popliteal artery and the posterior capsule of the knee. Used in combination with ACB in the ACB + iPACK group.
Poznan University of Medical Sciences
Poznan, Poland
RECRUITINGTime to First Rescue Analgesia
Time (in hours) from completion of the regional blocks to the first administration of a rescue analgesic (opioid or non-opioid) given for pain intensity ≥4 on the 0-10 Numerical Rating Scale (NRS).
Time frame: Within 48 hours after surgery.
Pain Intensity at Rest (NRS 0-10)
Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.
Time frame: 4 hours after surgery.
Pain Intensity at Rest (NRS 0-10)
Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.
Time frame: 8 hours after surgery.
Pain Intensity at Rest (NRS 0-10)
Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.
Time frame: 12 hours after surgery.
Pain Intensity at Rest (NRS 0-10)
Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.
Time frame: 24 hours after surgery.
Pain Intensity at Rest (NRS 0-10)
Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.
Time frame: 48 hours after surgery.
Pain Intensity During Movement (NRS 0-10)
Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.
Time frame: 4 hours after surgery.
Pain Intensity During Movement (NRS 0-10)
Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.
Time frame: 8 hours after surgery.
Pain Intensity During Movement (NRS 0-10)
Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.
Time frame: 12 hours after surgery.
Pain Intensity During Movement (NRS 0-10)
Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.
Time frame: 24 hours after surgery.
Pain Intensity During Movement (NRS 0-10)
Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.
Time frame: 48 hours after surgery.
Total Opioid Consumption
Cumulative dose of opioids converted to oral morphine milligram equivalents (MME).
Time frame: 0-48 hours after surgery.
Motor Function (Quadriceps Strength, MRC Scale)
Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.
Time frame: 4 hours after surgery.
Motor Function (Quadriceps Strength, MRC Scale)
Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.
Time frame: 8 hours after surgery.
Motor Function (Quadriceps Strength, MRC Scale)
Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.
Time frame: 12 hours after surgery.
Motor Function (Quadriceps Strength, MRC Scale)
Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.
Time frame: 24 hours after surgery.
Motor Function (Quadriceps Strength, MRC Scale)
Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.
Time frame: 48 hours after surgery.
Incidence of Postoperative Nausea and Vomiting (PONV)
Presence of nausea or vomiting requiring antiemetic therapy. Proportion of patients with at least one episode will be recorded.
Time frame: 0-48 hours after surgery.
Hemodynamic Adverse Events
Incidence of hypotension (systolic BP \<90 mmHg or \>30% decrease from baseline) and bradycardia (HR \<50/min) requiring treatment.
Time frame: From block placement until 24 hours after surgery.
Block-Related Adverse Events
Incidence of complications related to the regional blocks, including prolonged sensory or motor deficit, nerve injury (evaluated in outpatient clinic if required), hematoma, infection at the injection site, persistent weakness, or local anesthetic systemic toxicity.
Time frame: From block placement until 30 days after surgery.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.